1. Introduction
Breast cancer (BC) is the most common cancer in women globally, accounting for about a quarter of female cancer [ 1 , 2 ]. In spite of recent improvements in molecular and imaging diagnosis and treatments including hormone therapy, target therapy, chemotherapy, and radiotherapy, BC remains the leading cause of cancer death worldwide [ 1 – 3 ]. Based on the expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2 (HER2), and proliferation marker protein Ki-67, BC can be categorized into four subtypes including luminal A, luminal B, HER2, and triple-negative breast cancer (TNBC) [ 4 ].
TNBC is tested negative for ER, PR, and HER2 by immunohistochemical staining, accounting for 15-20% of BC cases [ 5 ]. Advanced breast cancer comprises inoperable locally advanced breast cancer and metastatic (stage IV) breast cancer. As shown in Figure 1(a) , the bone, the liver, and the lungs account, respectively, for about 67%, 40.8%, and 36.9% of the common metastatic sites, wherein basal-like BC (BLBC, accounting for 75% of the TNBC subtypes [ 6 ]) hits 40%, 35%, and 35%, respectively, of the metastatic BC [ 7 ]. More than 70% of the metastatic TNBC cases fails to survive after five years of diagnosis and exhibits worse prognosis than other BC subtypes [ 8 ]. Due to the lack of ER/PR/HER2 receptors, TNBC is unresponsive to endocrine and target therapy, such as tamoxifen, aromatase inhibitors, and/or anti-HER2-targeted therapies. As such, surgery, radiotherapy, and predominantly nonspecific chemotherapy (e.g., anthracycline and taxane regimens) remain the mainstay for management of these patients, yet with severe side effects worsening quality of life [ 9 , 10 ]. Although the combination uses of chemotherapy regimens (e.g., capecitabine in conjunction with taxanes) have shown increased response rates, the multiagent approach led to increased toxicities [ 11 , 12 ]. Therefore, treatments for TNBC have since a major challenge for oncologists due to the absence of unambiguous molecular targets.
Mitochondria are dynamic organelles that produce energy through oxidative phosphorylation (OXPHOS) for the sophisticated biochemical reactions of a cell. Originated from eubacterial endosymbiosis, each of them has multiple copies of mitochondrial DNA (mtDNA), which is a circular, double-stranded DNA (16,569-base pairs in human) encoding 37 genes, including 13 proteins, 22 tRNAs, and 2 rRNAs [ 13 ]. Structurally, mitochondria have double-membrane system, composed of outer membrane and inner membrane, which compartmentalize intermembrane space, crista, and matrix where OXPHOS takes place to generate ATP [ 13 ]. More than intracellular powerhouses, mitochondria play a central role in controlling physiological process and cellular fate by orchestrating metabolism, redox status, apoptosis, dynamics, mitophagy (a mechanism selectively degrading mitochondria by autophagy), mtDNA maintenance, and calcium balance [ 14 , 15 ]. More recently, approaches aiming at disturbances of cellular metabolism and mitochondrial functions for the treatment of cancer, including BC, have been emerging [ 15 , 16 ].
MicroRNAs (miRs) are small, approximately 22-nucleotide noncoding RNAs. miR genes are derived from within the introns and are subject to similar types of epigenetic regulation as are the protein-coding genes [ 17 ]. As shown in Figure 1(b) , a miR gene is initially transcribed by RNA polymerase II into a primary miRNA (pri-miRNA) and then processed in the nucleus by microprocessor complex comprising an endoribonuclease Drosha and a double-stranded RNA-binding protein DiGeorge syndrome critical region 8 (DGCR8) into a ~70 nt precursor miR (pre-miR) [ 18 ], which are then exported to the cytoplasm by an exportin 5/guanosine 5′-triphosphate (XPO5/RanGTP) complex. In the cytoplasm, the loop of a pre-miRNA is cleaved by the endonuclease Dicer to generate a mature miR [ 19 ]. The regulatory functions of a mature miR are accomplished by associating with the Argonaute (AGO) of the RNA-induced silencing complex (RISC) [ 20 ]. As such, a miR ultimately targets a strand of mRNA by base pairing its 3′ untranslated region (UTR) and negatively regulates mRNA expression in most cases. When bound to an mRNA, RISC inhibits translation, yet the main effect is to degrade the mRNA through deadenylation [ 17 ].
mitomiRs are a group of miRs that intimately regulate mitochondrial functions. mitomiRs can exert the repressive effect on gene expression to modulate mitochondrial functions by two ways: one major type of mitomiRs targets mRNAs in the cytoplasm; the other type of mitomiRs is imported into mitochondria to target mtDNA-encoded mRNAs. With regard to the gene origin of the mitomiRs, the vast majority of them are nuclear-encoded, while few of the mitomiRs are encoded by mtDNA (e.g., miR-1974, miR-1977, and miR-1978) [ 21 ].
Mounting evidence in recent years has noted the translational implication of mitomiRs in metabolic disorder, degenerative diseases, and cancer [ 22 – 24 ]. Their functions in modulating multiple aspects of mitochondrial homeostasis permit alterations in cancer metabolism, growth, metastasis, and sensitivity to clinical drugs. More importantly, mitomiRs' potential as a predictive panel and therapeutic targets is notably emerging. As such, we herein focus on the novel biological roles and mechanisms of mitomiRs on the mitochondria-centric metabolic network in the context of TNBC ( Figure 1 ). Moreover, we highlight recent insights into the advanced understating of predictive value and therapeutic implication of mitomiRs.
2. Roles of mitomiRs in Regulating Metabolic Reprogramming of TNBC
Cancer cells are characterized by significant metabolic reprogramming which facilitate survival and rapid proliferation in a nutrient-deprived tumor microenvironment [ 25 , 26 ]. Otto Warburg firstly identified that cancer cells maintain high levels of glycolysis for ATP production, regardless of oxygen availability, a phenomenon thereafter termed as the Warburg effect [ 27 ]. Since then, an increasing volume of study focused on cancer-associated metabolic reprogramming within crucial metabolic pathways, including altered metabolism of glucose, fatty acid, and amino acids as well as perturbed OXPHOS, in an attempt to find out metabolic susceptibilities during cancer progression. The potential preclinical/clinical reagents targeting metabolic reprogramming of TNBC have been reviewed (32296646). In this regard, we summarized a number of mitomiRs that have been reported to significantly regulate TNBC progression by acting to metabolic reprogramming ( Table 1 ).
Several lines of study noted that mitomiRs perturb glycolysis-associated targets to inhibit TNBC. Jiang et al. have demonstrated that miR-155/miR-143 axis modulates tumor development by dictating glycolysis [ 40 ]. They showed that miR-155 and miR-143 have TNBC-promoting and TNBC-inhibiting effect, respectively. Mechanistically, tumorigenic inflammatory signals augment glycolysis through miR-155, which suppresses miR-143 by targeting CCAAT-enhancer-binding protein β (C/EBP β ). The resulting decrease in miR-143 leads to an unleashed targeting inhibition on hexokinase 2 (HK2), leading to an increase in HK2 and consequently an induced glycolysis [ 40 ]. miR-18a was demonstrated to inhibit TNBC growth and metastasis in both in vivo and in vitro models and expression of hypoxic genes [ 39 ]. The molecular basis of miR-18a lies in the direct binding to the HIF1A UTR [ 39 ]. Inhibition of TNBC proliferation in vitro can be achieved by the overexpression of miR-101, which exerts repressive effect on gene expression of AMPK [ 38 ]. Yu et al. have shown that miR-340 inhibits glycolysis through modulating mitochondrial calcium homeostasis in TNBC [ 37 ]. Specifically, miR-340 targets the UTR of mitochondrial calcium uniporter (MCU) gene and represses the expression to reduce tumor growth and metastasis [ 37 ]. Li et al. demonstrated that miR-30a inhibits glycolysis and enhances mitochondrial respiratory activity by targeting lactate dehydrogenase A (LDHA), whereby the growth and metastasis of TNBC is reduced [ 35 ]. miR-342 was reported to disturb glucose metabolism and lactate uptake of TNBC by targeting monocarboxylate transporter 1 (MCT1) [ 34 ]. miR-128 was shown to specifically inhibit insulin receptor (INSR) and insulin receptor substrate 1 (IRS1) to abate glycolytic signaling pathway and mitochondrial respiration, resulting in decreased tumor growth [ 33 ]. Both miR-148a and miR-152 were shown to directly target pyruvate kinase M1/2 (PKM2) to counteract glycolytic metabolism of TNBC cells, leading to decreased cancer cell proliferation and angiogenesis [ 46 ]. Yao et al. have identified that let-7a represses signal transducers and activators of transcription 3 (STAT3) expression level to subsequently mediate hnRNPA1/PKM2 signaling, leading to a decrease in glucose metabolism and TNBC proliferation [ 31 ]. miR-140 showed antiglycolytic and antiproliferative effect on TNBC through direct binding to glucose transporter 1 (GLUT1) [ 30 ]. Li et al. showed that miR34a inhibitor promotes cell proliferation and glucose uptake, indicating the anti-TNBC effect of miR34a [ 47 ]. More recently, Wang et al. demonstrated that miR-29a overexpression exerts inhibitory effect on proliferation, migration, and invasion of TNBC cells through targeting the anterior gradient 2 (ARG2)/HIF-1 α axis [ 28 ]. Furthermore, circular RNA circPVT1 was identified as a miR sponge, leading to suppressing the expression of miR-29a and promoting in vivo tumor growth [ 28 ].
In addition to glucose metabolism, some mitomiRs act toward fatty acid metabolism to exert inhibitory effect on TNBC. For example, miR-195 was shown to target acetyl-CoA carboxylase (ACACA), fatty acid synthase (FASN), and 3-hydroxy-3-methylglutaryl CoA reductase (HMGCR) to suppress epithelial-mesenchymal transition (EMT), proliferation, migration, and invasion [ 43 ]. Serguienko et al. have demonstrated that let-7a targets SCD (stearoyl-CoA desaturase) to reduce cell proliferation and sensitivity to doxorubicin [ 42 ]. More recently, Chen et al. reported that miR-1291 targets estrogen-related receptor alpha (ERR α ) to inhibit the expression level of carnitine palmitoyltransferase 1C (CPT1C), causing a decrease in cell proliferation in vitro and tumor growth in vivo [ 41 ].
With regard to amino acid metabolism, Ueda et al. demonstrated that miR-27a play a suppressive role over TNBC by disturbing glutamine/cystine dynamics. Specifically, miR-27a directly bind to UTR of cystine/glutamate transporter (xCT) and cystathionine gamma-lyase (CTH), whereby cystine uptake and production, respectively, are compromised, leading to a decrease in mammosphere formation and cancer stem cell markers as well as an increase in sensitivity to doxorubicin and paclitaxel [ 36 ]. On the other hand, some mitomiRs were shown to curb TNBC by impeding OXPHOS. miR-4485 and miR-663 have been identified to hinder mitochondrial function by direct binding to the UTR of mtDNA-encoded 16S rRNA and ubiquinol-cytochrome c reductase complex assembly factor 2 (UQCC2), respectively [ 44 , 45 ].
In contrast, some reports have explored that a group of mitomiRs responsible for metabolic reprogramming can act to promote the development of TNBC. In this regard, miR-21 was shown to exert its function by targeting calcium-binding protein 39-like (CAB39L) and sestrin-1 (SESN1) to promote proliferation and invasion of TNBC [ 48 ]. Kim et al. have reported that miR-155 promotes glycolysis and growth of TNBC by targeting an axis comprising phosphoinositide 3-kinase regulatory subunit 1, forkhead box O, and c-MYC (PI3R1-FOXO3a-cMYC axis) [ 32 ]. A recent report conducted by Du et al. identified that miR-210 exerts a positive effect in glucose metabolism, lactate production, extracellular acidification rate (ECAR), proliferation, and starvation-induced apoptosis. The molecular underpinnings were found to lie in direct binding of miR-210 to GPD1L and CYGB, whereby HIF-1 α stabilization and p53 suppression can, respectively, be maintained [ 29 ]. An integrative network summarizing the roles and pathways of mitomiRs is illustrated in Figure 2 .
3. Roles of mitomiRs in Redox Homeostasis and Cell Apoptosis
The increased demand for cellular ATP and accelerated oxidation of nutrient molecules trigger the generation of reactive oxygen species (ROS) derived from electron transport chain of mitochondria [ 49 ]. A moderate elevated ROS benefits cellular proliferation, whereas excessive ROS production can lead to oxidative damage to proteins, lipids, and DNA [ 50 ]. As such, intracellular ROS status plays a critical role in cell growth and survival. Indeed, a cluster of miRs functions to dictate the imbalance between the production of ROS and the activity of antioxidant defence system, resulting in the disruption of redox homeostasis and ultimately cancer cell apoptosis [ 22 ]. A study conducted by Eades et al. has demonstrated that miR-200a serves as repressor on TNBC cells by perturbing antioxidant defence mechanism [ 51 ]. Specifically, miR-200a directly targets Kelch-like ECH-associated protein 1 (KEAP1), leading to the NF-E2-related factor 2 (NRF2) stabilization and nuclear translocation to act forward the activation of Nrf2-dependent NAD(P)H-quinone oxidoreductase 1 (NQO1) gene transcription [ 51 ]. By targeting SCD, let-7a is able to alter fatty acid metabolism, leading to boosted mitochondrial activity and oxidative stress, as evidenced by an increase in oxygen consumption rate (OCR), ROS expression level, and the expression level of superoxide dismutase 2 (SOD2), thioredoxin reductase 1 (TXRND1), and heme oxygenase 1 (HO-1) [ 42 ]. Likewise, miR-27a was shown to disrupt glutathione- (GSH-) associated antioxidant mechanism by targeting xCT, which mediates the uptake of cystine, a precursor for GSH biosynthesis [ 36 ]. miR-324 has been reported to induce ROS level through inhibiting a driver of tumor progression, activated CDC42 kinase 1 (ACK1) [ 52 ]. In contrast, miR-373 plays an anti-ROS role in TNBC by targeting thioredoxin-interacting protein (TXNIP), which functions to inhibit antioxidant protein thioredoxin (Trx) by interacting with its redox-specific active cysteine residues [ 53 ]. The ROS-suppressing hallmark of miR-373/TXNIP acted to promote HIF-1 α /twist family BHLH transcription factor 1 (TWIST1) pathway, leading to increased invasive behaviour of TNBC cells [ 53 ].
Furthermore, some mitomiRs induce ROS production by targeting genes involved in the integrity of mitochondria. In this regard, miR-4485 was demonstrated to translocate to mitochondria to exert direct binding activity to mtDNA-encoded 16S rRNA, resulting in a decrease in electron transport chain (ETC) enzyme activity and mitochondrial ATP production, as well as an increase in expression level of ROS [ 44 ]. The tumor-suppressive effect in vivo was verified by overexpression of miR-4485 in TNBC cells [ 44 ]. In addition, Ahir et al. recently identified that miR-34a is implicated in effectively suppressing growth and mammosphere formation of TNBC [ 54 ]. The inhibitory role of miR-34a on B cell lymphoma 2 (BCL-2) permits the formation of permeabilization pore on the outer membrane of the mitochondria (OMM), promoting the intracellular ROS production [ 54 ]. Table 2 summarizes the mitomiRs acting toward the regulation of redox homeostasis and the biological roles and mechanisms in TNBC.
Several lines of study have revealed a group of mitomiRs modulate the carcinogenesis and sensitivity to drugs of TNBC by targeting genes implicated in apoptotic signaling. Liu et al. have demonstrated that miR-101 play a positive role in the induction of TNBC apoptosis by targeting induced myeloid leukemia cell differentiation protein Mcl-1 (MCL-1), a prosurvival member of the Bcl-2 family [ 55 ]. Overexpression of miR-101 was shown to inhibit tumor growth and sensitize cells to paclitaxel-induced apoptosis [ 55 ]. Similarly, Zheng et al. demonstrated that miR-145 has a promotive role in receptor-interacting protein Fas-associated protein with death domain caspase-8 (RIP1-FADD-casp8) apoptosis signaling induced by TNF- α [ 56 ]. By targeting cellular inhibitor of apoptosis (cIAP1), miR-145 can exert TNBC-suppressive function, leading to the activation of the extrinsic pathway, whereby activated casp8 act to cleave BH3 interacting-domain death agonist (BID) to initiate the mitochondrial apoptotic pathway [ 56 ]. miR-233 has been shown to specifically suppress the expression of HCLS1-associated protein X-1 (HAX-1), an antiapoptotic protein that inhibits the activation of caspase-9 [ 57 ]. miR-223 overexpression potentiated proapoptotic effect induced by TNF-related apoptosis-inducing ligand (TRAIL) over triple-negative breast cancer stem cells (TNBCSCs) [ 57 ]. Patel el al. revealed that miR-15a/miR-16 overexpression in TNBC cells results in increased intrinsic pathway of apoptosis through direct of B cell-specific Moloney murine leukemia virus integration site 1 (BMI1), an oncogene involving mitochondrial homeostasis [ 58 ]. miR-20b was shown to target VEGF and cause deceased BCL-2 and increased BAX and activation of cell apoptosis, resulting in an inhibitory effect on proliferation, migration, and invasion of TNBC cells [ 59 ]. Both groups, Ahir et al. and Majzoub et al., have recently shown that BCL-2 is a specific target of miR-34a [ 54 ] and miR-125a/miR-181a [ 55 ]. These mitomiRs can exert suppressive effect on TNBC cells by inducing apoptosis as well as reducing cell migration [ 55 ] and tumor growth [ 54 ]. Conversely, miR-224 has been reported to be tumor-promotive in TNBC. Zhang et al. showed that miR-224 provides apoptotic resistance and enhances proliferation, migration, and invasion by targeting caspase-9 [ 60 ]. Collectively, the recent understandings of mitomiRs in targeting apoptosis pathway in the context of TNBC are listed in Table 3 . The schematic sophisticated network encompassing tumor-suppressive/tumor-promotive mitomiRs targeting molecules central to redox homeostasis and apoptosis is illustrated in Figure 3 .
4. Roles of mitomiRs in Regulating Mitochondrial Dynamics and Mitophagy
Mitochondria are highly dynamic organelles. The dynamic properties comprising fusion, fission, and degradation not only play critical role for their optimal function in energy generation but also have profound impact on human diseases, including cancer [ 61 ]. The multiple events of mitochondrial fusion require hydrolysis of GTP and mitochondrial membrane potential [ 62 ]. Mitofusins 1 and 2 (MFN1/2) are both GTP-hydrolyzing enzymes of the dynamin superfamily. They are located on the outer membrane of mitochondria (OMM) and required for OMM fusion [ 63 ]. The fusion of inner membrane of mitochondria (IMM) is mediated by another member of the dynamin superfamily, optic atrophy 1 (OPA1), located in IMM [ 64 ]. On the other hand, the mitochondrial fission largely relied on the activity of dynamin-related protein 1 (DRP1), a GTP-hydrolyzing enzyme [ 65 , 66 ]. DRP1 is recruited from the cytosol to associate with corresponding receptors residing on OMM, including mitochondrial fission 1 protein (FIS1), mitochondrial fission factor (MFF), mitochondrial dynamics protein MID49 (MID49), and mitochondrial dynamics protein MID51 (MID51) [ 67 – 69 ]. Mitochondrial fission acts to promote segregation of damaged mitochondria, which subsequently facilitates mitochondrial fragments of the appropriate size for engulfment by autophagosomes. The degradation of dysfunctional mitochondria by autophagy, or mitophagy, is a major mechanism for mitochondrial quality control [ 61 ].
More recently, the emerging role of mitomiRs in TNBC progression via regulating the mitochondrial quality control machinery has been revealed ( Figure 4 ). In this regard, Purohit et al. reported that miR-195 exerts anti-TNBC effect by targeting NFN2. The dysregulated mitochondrial dynamics was evidenced by decreased MFN2 and OPA1, increased DRP1, and enhanced mitochondrial fission. miR-195 also led to declined mitochondrial OXPHOS and bioenergetics and increased ROS level and cell apoptosis [ 70 ]. Zhang et al. demonstrated that overexpression of miR-1 exerts a tumor-suppressive effect by simultaneously targeting mitophagy-associated genes including MINOS1 (mitochondrial inner membrane organizing system 1), GPD2 (glycerol-3-phosphate dehydrogenase 2), and LRPPRC (leucine-rich pentatricopeptide-repeat containing), leading to an induction of mitophagy in breast cancer stem cells [ 71 ]. On the other hand, Hu et al. showed that miR-137 play a tumor-promotive role in breast cancer stem cells [ 72 ]. By direct targeting FUN14 domain containing 1 (FUNDC1), miR-137 repressed the mitophagy by reducing the expression of FUNDC1, NIP-3-like protein X (NIX), and LC3-II, resulting in an increase in mitochondrial biogenesis and bioenergetics and a decrease in ROS level and cell apoptosis [ 72 ]. Table 4 highlights the mitomiRs involved in mitochondrial dynamic and mitophagy.
5. mitomiRs and Calcium Transport
A growing body of literature has revealed the implications of mitochondrial calcium uptake in tumorigenesis [ 73 ]. Indeed, some of the studies unravelled the roles of a cluster of mitomiRs in inhibiting TNBC progression by disturbing mitochondrial calcium uptake. Table 4 outlines the recent findings regarding this issue. Specifically, Singh et al. demonstrated that miR-195 acts toward increased mitochondrial calcium by targeting cytochrome P450 family 27, subfamily B, polypeptide 1 (CYP27B1), leading to dysfunctional mitochondria as evidenced by loss of mitochondrial membrane potential. They confirmed its antitumor role by showing that overexpression of miR-195 impedes EMT, proliferation, migration, and invasion of TNBC cells [ 43 ]. Yu et al. showed that miR-340 negatively regulates mitochondrial calcium uniporter (MCU) by direct interacting with MCU 3′UTR. Downregulated MCU was shown to inhibit tumor Warburg effect, leading to a significant decrease in cell migration and invasion in vitro and lung metastasis in vivo [ 37 ]. Interestingly, Zheng el al. revealed that knockdown of MCU induces generation and secretion of miR-4488-containing extracellular vesicles (EVs) from TNBC cells. The miR-4488-containing EVs uptaken by endothelial cells acted to target an angiogenic activator C-X3-C motif chemokine ligand 1 (CX3CL1), resulting in suppressed angiogenic activity. Furthermore, the administration of miR-4488-containing EVs inhibited tumor metastasis and increased survival time of tumor-bearing mice [ 74 ]. The schematic pipeline regarding the roles and mechanisms of mitomiRs directing at mitochondrial calcium balance is illustrated in Figure 5 .
6. mitomiRs and mtDNA Maintenance
A line of research identified a group of mitomiRs functioning to modulate the maintenance of mtDNA in the context of TNBC ( Table 4 ). Sripada et al. showed that miR-4485 suppresses tumor growth and cell proliferation of TNBC by targeting 16S rRNA encoded by mtDNA [ 44 ]. Fan et al. demonstrated that miR-199a directly targets mitochondrial transcription factor A (TFAM) and causes a significant decrease in mtDNA content, leading to reduced proliferation and potentiate proapoptotic effect induced by cisplatin [ 75 ]. In addition, Xiao et al. reported that miR-128 exerts a mtDNA-reducing effect through targeting INSR/IRS1, resulting in a decrease in mitochondrial bioenergetics, proliferation, and tumor growth of TNBC [ 33 ]. More recently, miR-499a was identified as a driver of TNBCSC development. In this regard, Manda et al. showed that miR-499a acts to mediate the suppression of DNA polymerase beta (POLB), which plays a master role in the repair and genome stability of mtDNA [ 76 ]. We summarized the mechanisms of mitomiRs acting on mtDNA maintenance of TNBC in Figure 5 .
7. Prognostic Value, Therapeutic Implications, and Future Perspective
The expression of several mitomiRs can potentially be regarded as predictive, diagnostic, and prognostic biomarkers for TNBC ( Table 5 ). A cluster of low-expressed mitomiRs is identified in tumor tissue [ 28 , 33 , 34 , 44 – 47 , 52 , 55 , 71 , 77 – 79 ], while some of them are high-expressed [ 32 , 53 , 79 , 80 ]. Of note, some mitomiRs showed clinical significance in predicting disease outcome. There are a group of mitomiRs enabling predicting survival time [ 33 , 34 , 45 , 47 , 77 ], while another set of them indicates advanced stage or metastasis [ 52 , 53 , 55 ]. Importantly, circulating mitomiRs identified as relevant biomarkers provide an opportunity to establish a rapid clinical panel which can be less invasive and more accessible [ 47 , 48 , 74 , 79 – 81 ].
Recent insights into therapeutic approaches in preclinical model pave new paths to potential treatments for TNBC ( Table 6 ). These strategies exert treatment effect by targeting various aspects implicated in mitochondrial homeostasis, including metabolic reprogramming, apoptosis, redox signaling, and mitochondrial calcium transport. Most common approaches employed genetic manipulation, including siRNA, shRNA, and antisense for mitomiR inhibition [ 28 , 52 , 59 , 80 ]. Although some approaches conducted by virus-based gene delivery demonstrated treatment efficiency [ 33 , 82 ], the potential adverse effects to humans must be taken into consideration in the future should they be registered for clinical trials. The use of chemotherapeutics combo could be promising but still need more advanced study, such as in vivo model (31541355). Nanoparticle-loaded mitomiRs provide a potential way to achieve highly efficient delivery into tumor (32319481). Interestingly, Ahir et al. demonstrated a mitomiR-promoting nanotechnology using copper oxide nanowire fabricated with folic acid (CuO-Nw-FA) that enables enhanced cellular uptake in TNBC cells without imparting significant toxicity in normal cellular system [ 83 ]. Oral hypoglycemic drug [ 48 ], natural products [ 76 , 84 ], epigenetic modifier [ 51 ], and physical agent [ 85 ] have been shown to effectively inhibit TNBC cell proliferation. More notably, the notion of using mitomiR-containing EVs may offer a treatment strategy with advantage of high purity, specificity, and biodistribution as less safety concern [ 74 ]. Of note, some clinical trials utilizing mitomiR-based treatment for several types of cancer have been registered ( Table 7 ). Unfortunately, due to the occurrence of immune-related serious adverse events, the trial using miR-34a was terminated ( NCT01829971 ). The termination of anti-miR-155-based drug is due to business reasons, but not concerns regarding safety or lack of efficacy ( NCT03713320 ). The miR-26-based approach, TargomiRs, may be a next glimmer of hope for cancer treatment. The first-in-human, phase 1 trial of TargomiR patients with malignant pleural mesothelioma has completed. The results showed acceptable safety profile and early signs of activity of TargomiRs in patients [ 86 ], supporting the feasibility of further study.
8. Conclusions
Due to the absence of unambiguous molecular targets for TNBC, its clinical treatment is still a challenging issue. The hallmarks of altered metabolism and mitochondrial fitness in TNBC provide an opportunity for advancing new diagnostic/prognostic tools and therapeutic approaches. mitomiRs are a subgroup of microRNAs that closely regulate mitochondrial functionality by targeting genes present in the cytosol or mitochondria. Growing evidence has elucidated its effectiveness and mechanism of action in the context of TNBC, making mitomiRs an emerging field of study. Indeed, the predictive, prognostic, and diagnostic value of a number of mitomiRs has been revealed. There is increasing novel mitomiR-based therapeutics aiming for efficient inhibition on tumor growth. It is important to note that some mitomiRs were qualified for the early stage of clinical trial. In spite of these inspiring advances, there is still a need to gain deeper insight into mitomiR-dictated mechanisms with respect to mitochondrial homeostasis, to develop accessible prediction panel with satisfactory sensitivity/specificity and to explore interventions suitable for clinical use. To summarize, mitomiRs represent attractive therapeutic targets for the treatment of TNBC.
Acknowledgments
The authors would like to thank James Waddell for his assistance with the proofreading and revision of this article. This research was funded by the Ministry of Science and Technology, Taiwan (MOST 106-2314-B-442-001-MY3, MOST 109-2314-B-442-001, and MOST 109-2314-B-075B-002), National Health Research Institutes (NHRI-109BCCO-MF-202015-01), and Show Chwan Memorial Hospital, Taiwan (SRD-109023, SRD-109024, SRD-109025, and RD107063).
Data Availability
No data were used to support this study.
Conflicts of Interest
The authors declare that there is no conflict of interest regarding the publication of this paper.
1 Fitzmaurice C. Abate D. Abbasi N. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017 JAMA Oncology 2019 5 12 1749 1768 10.1001/jamaoncol.2019.2996 2-s2.0-85072768207 31560378 PMC6777271
2 Bray F. Ferlay J. Soerjomataram I. Siegel R. L. Torre L. A. Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA: a Cancer Journal for Clinicians 2018 68 6 394 424 10.3322/caac.21492 2-s2.0-85053395052 30207593
3 Torre L. A. Siegel R. L. Ward E. M. Jemal A. Global cancer incidence and mortality rates and trends--an update Cancer Epidemiology, Biomarkers & Prevention 2016 25 1 16 27 10.1158/1055-9965.EPI-15-0578 2-s2.0-84955299344 26667886
4 Goldhirsch A. Wood W. C. Coates A. S. Gelber R. D. Thurlimann B. Senn H. J. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 Annals of Oncology 2011 22 8 1736 1747 10.1093/annonc/mdr304 2-s2.0-79960980007 21709140 PMC3144634
5 Fabbri F. Salvi S. Bravaccini S. Know your enemy: genetics, aging, exposomic and inflammation in the war against triple negative breast cancer Seminars in Cancer Biology 2020 60 285 293 10.1016/j.semcancer.2019.10.015 31669505
6 Angius A. Cossu-Rocca P. Arru C. Modulatory role of microRNAs in triple negative breast cancer with basal-like phenotype Cancers 2020 12 11 p. 3298 10.3390/cancers12113298 33171872 PMC7695196
7 Harbeck N. Penault-Llorca F. Cortes J. Breast cancer Nature Reviews. Disease Primers 2019 5 1 p. 66 10.1038/s41572-019-0111-2 2-s2.0-85072553302 31548545
8 Bonotto M. Gerratana L. Poletto E. Measures of outcome in metastatic breast cancer: insights from a real-world scenario The Oncologist 2014 19 6 608 615 10.1634/theoncologist.2014-0002 2-s2.0-84901935639 24794159 PMC4041678
9 Brenton J. D. Carey L. A. Ahmed A. A. Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? Journal of Clinical Oncology 2005 23 29 7350 7360 10.1200/JCO.2005.03.3845 2-s2.0-28344454000 16145060
10 Jitariu A. A. Cimpean A. M. Ribatti D. Raica M. Triple negative breast cancer: the kiss of death Oncotarget 2017 8 28 46652 46662 10.18632/oncotarget.16938 2-s2.0-85022182908 28445140 PMC5542300
11 Bianchini G. Balko J. M. Mayer I. A. Sanders M. E. Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease Nature Reviews. Clinical Oncology 2016 13 11 674 690 10.1038/nrclinonc.2016.66 2-s2.0-84994112876 27184417 PMC5461122
12 Conlin A. K. Seidman A. D. Taxanes in breast cancer: an update Current Oncology Reports 2007 9 1 22 30 10.1007/BF02951422 2-s2.0-33846137668 17164044
13 Andrews R. M. Kubacka I. Chinnery P. F. Lightowlers R. N. Turnbull D. M. Howell N. Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA Nature Genetics 1999 23 2 p. 147 10.1038/13779 2-s2.0-0032868141 10508508
14 Tait S. W. Green D. R. Mitochondrial regulation of cell death Cold Spring Harbor Perspectives in Biology 2013 5 9 10.1101/cshperspect.a008706 2-s2.0-84883755553 24003207 PMC3753705
15 Rodrigues T. Ferraz L. S. Therapeutic potential of targeting mitochondrial dynamics in cancer Biochemical Pharmacology 2020 182 p. 114282 10.1016/j.bcp.2020.114282 33058754
16 Reda A. Refaat A. Abd-Rabou A. A. Role of mitochondria in rescuing glycolytically inhibited subpopulation of triple negative but not hormone-responsive breast cancer cells Scientific Reports 2019 9 1 p. 13748 10.1038/s41598-019-50141-z 2-s2.0-85072612709 31551501 PMC6760198
17 Goodall G. J. Wickramasinghe V. O. RNA in cancer Nature Reviews. Cancer 2021 21 1 22 36 10.1038/s41568-020-00306-0 33082563
18 Carthew R. W. Sontheimer E. J. Origins and mechanisms of miRNAs and siRNAs Cell 2009 136 4 642 655 10.1016/j.cell.2009.01.035 2-s2.0-60149088848 19239886 PMC2675692
19 Saito K. Ishizuka A. Siomi H. Siomi M. C. Processing of pre-microRNAs by the Dicer-1-Loquacious complex in Drosophila cells PLoS Biology 2005 3 7, article e235 10.1371/journal.pbio.0030235 2-s2.0-22744454230 15918769 PMC1141268
20 Li S. Lian S. L. Moser J. J. Identification of GW182 and its novel isoform TNGW1 as translational repressors in Ago2-mediated silencing Journal of Cell Science 2008 121 24 4134 4144 10.1242/jcs.036905 2-s2.0-59349083988 19056672 PMC7695043
21 Bandiera S. Ruberg S. Girard M. Nuclear outsourcing of RNA interference components to human mitochondria PLoS One 2011 6 6, article e20746 10.1371/journal.pone.0020746 2-s2.0-79958737573 21695135 PMC3113838
22 Lu C. Zhou D. Wang Q. Crosstalk of microRNAs and oxidative stress in the pathogenesis of cancer Oxidative Medicine and Cellular Longevity 2020 2020 13 2415324 10.1155/2020/2415324 32411322 PMC7204110
23 Ortega M. A. Fraile-Martinez O. Guijarro L. G. The regulatory role of mitochondrial microRNAs (MitomiRs) in breast cancer: translational implications present and future Cancers 2020 12 9 p. 2443 10.3390/cancers12092443 32872155 PMC7564393
24 Purohit P. K. Saini N. Mitochondrial microRNA (MitomiRs) in cancer and complex mitochondrial diseases: current status and future perspectives Cellular and Molecular Life Sciences 2021 78 4 1405 1421 10.1007/s00018-020-03670-0 33084945 PMC11072739
25 DeBerardinis R. J. Chandel N. S. Fundamentals of cancer metabolism Science Advances 2016 2 5, article e1600200 10.1126/sciadv.1600200 2-s2.0-84990224053 27386546 PMC4928883
26 Pavlova N. N. Thompson C. B. The emerging hallmarks of cancer metabolism Cell Metabolism 2016 23 1 27 47 10.1016/j.cmet.2015.12.006 2-s2.0-84955326448 26771115 PMC4715268
27 Koppenol W. H. Bounds P. L. Dang C. V. Otto Warburg’s contributions to current concepts of cancer metabolism Nature Reviews. Cancer 2011 11 5 325 337 10.1038/nrc3038 2-s2.0-79955398591 21508971
28 Wang J. Huang K. Shi L. Zhang Q. Zhang S. <p>CircPVT1 promoted the progression of breast cancer by regulating MiR-29a-3p-mediated AGR2-HIF-1 α pathway</p> Cancer Management and Research 2020 Volume 12 11477 11490 10.2147/CMAR.S265579 33223849 PMC7672658
29 Du Y. Wei N. Ma R. Jiang S. Song D. A miR-210-3p regulon that controls the Warburg effect by modulating HIF-1 α and p53 activity in triple-negative breast cancer Cell Death & Disease 2020 11 9 p. 731 10.1038/s41419-020-02952-6 32908121 PMC7481213
30 He Y. Deng F. Zhao S. Analysis of miRNA-mRNA network reveals miR-140-5p as a suppressor of breast cancer glycolysis via targeting GLUT1 Epigenomics 2019 11 9 1021 1036 10.2217/epi-2019-0072 2-s2.0-85068662067 31184216
31 Yao A. Xiang Y. Si Y. R. PKM2 promotes glucose metabolism through a let-7a-5p/Stat3/hnRNP-A1 regulatory feedback loop in breast cancer cells Journal of Cellular Biochemistry 2019 120 4 6542 6554 10.1002/jcb.27947 2-s2.0-85055712250 30368881
32 Kim S. Lee E. Jung J. MicroRNA-155 positively regulates glucose metabolism via PIK3R1-FOXO3a-cMYC axis in breast cancer Oncogene 2018 37 22 2982 2991 10.1038/s41388-018-0124-4 2-s2.0-85043370173 29527004 PMC5978802
33 Xiao M. Lou C. Xiao H. MiR-128 regulation of glucose metabolism and cell proliferation in triple-negative breast cancer The British Journal of Surgery 2018 105 1 75 85 10.1002/bjs.10646 2-s2.0-85033500103 29116653
34 Romero-Cordoba S. L. Rodriguez-Cuevas S. Bautista-Pina V. Loss of function of miR-342-3p results in MCT1 over-expression and contributes to oncogenic metabolic reprogramming in triple negative breast cancer Scientific Reports 2018 8 1 p. 12252 10.1038/s41598-018-29708-9 2-s2.0-85051751711 30115973 PMC6095912
35 Li L. Kang L. Zhao W. miR-30a-5p suppresses breast tumor growth and metastasis through inhibition of LDHA-mediated Warburg effect Cancer Letters 2017 400 89 98 10.1016/j.canlet.2017.04.034 2-s2.0-85019066492 28461244
36 Ueda S. Takanashi M. Sudo K. Kanekura K. Kuroda M. miR-27a ameliorates chemoresistance of breast cancer cells by disruption of reactive oxygen species homeostasis and impairment of autophagy Laboratory Investigation 2020 100 6 863 873 10.1038/s41374-020-0409-4 32066826
37 Yu C. Wang Y. Peng J. Mitochondrial calcium uniporter as a target of microRNA-340 and promoter of metastasis via enhancing the Warburg effect Oncotarget 2017 8 48 83831 83844 10.18632/oncotarget.19747 2-s2.0-85031036972 29137386 PMC5663558
38 Liu P. Ye F. Xie X. mir-101-3p is a key regulator of tumor metabolism in triple negative breast cancer targeting AMPK Oncotarget 2016 7 23 35188 35198 10.18632/oncotarget.9072 2-s2.0-84973661688 27145268 PMC5085220
39 Krutilina R. Sun W. Sethuraman A. MicroRNA-18a inhibits hypoxia-inducible factor 1 α activity and lung metastasis in basal breast cancers Breast Cancer Research 2014 16 4 p. R78 10.1186/bcr3693 2-s2.0-84904771973 25069832 PMC4405876
40 Jiang S. Zhang L. F. Zhang H. W. A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells The EMBO Journal 2012 31 8 1985 1998 10.1038/emboj.2012.45 2-s2.0-84862812020 22354042 PMC3343331
41 Chen Y. Zhou Y. Han F. A novel miR-1291-ERR α -CPT1C axis modulates tumor cell proliferation, metabolism and tumorigenesis Theranostics 2020 10 16 7193 7210 10.7150/thno.44877 32641987 PMC7330864
42 Serguienko A. Grad I. Wennerstrom A. B. Metabolic reprogramming of metastatic breast cancer and melanoma by let-7a microRNA Oncotarget 2015 6 2451 2465 10.18632/oncotarget.3235 2-s2.0-84922971651 25669981 PMC4385863
43 Singh R. Yadav V. Kumar S. Saini N. MicroRNA-195 inhibits proliferation, invasion and metastasis in breast cancer cells by targeting FASN, HMGCR, ACACA and CYP27B1 Scientific Reports 2015 5 1 p. 17454 10.1038/srep17454 2-s2.0-84949294648 PMC4668367 26632252
44 Sripada L. Singh K. Lipatova A. V. hsa-miR-4485 regulates mitochondrial functions and inhibits the tumorigenicity of breast cancer cells Journal of Molecular Medicine (Berlin, Germany) 2017 95 6 641 651 10.1007/s00109-017-1517-5 2-s2.0-85013173168 28220193
45 Carden T. Singh B. Mooga V. Bajpai P. Singh K. K. Epigenetic modification of miR-663 controls mitochondria-to-nucleus retrograde signaling and tumor progression The Journal of Biological Chemistry 2017 292 50 20694 20706 10.1074/jbc.M117.797001 2-s2.0-85038351857 29066618 PMC5733605
46 Xu Q. Liu L. Z. Yin Y. Regulatory circuit of PKM2/NF- κ B/miR-148a/152-modulated tumor angiogenesis and cancer progression Oncogene 2015 34 43 5482 5493 10.1038/onc.2015.6 2-s2.0-84945467833 25703326
47 Li Z. Gong X. Zhang W. Inhibition of miRNA-34a promotes triple negative cancer cell proliferation by promoting glucose uptake Experimental and Therapeutic Medicine 2019 18 3936 3942 10.3892/etm.2019.8017 31616515 PMC6781812
48 Pulito C. Mori F. Sacconi A. Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activities Cell discovery 2017 3 1 p. 17022 10.1038/celldisc.2017.22 2-s2.0-85021772107 PMC5501975 28698800
49 Barja G. Mitochondrial oxygen radical generation and leak: sites of production in states 4 and 3, organ specificity, and relation to aging and longevity Journal of Bioenergetics and Biomembranes 1999 31 4 347 366 10.1023/a:1005427919188 2-s2.0-0033369476 10665525
50 Trachootham D. Alexandre J. Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nature Reviews. Drug Discovery 2009 8 7 579 591 10.1038/nrd2803 2-s2.0-67650071137 19478820
51 Eades G. Yang M. Yao Y. Zhang Y. Zhou Q. miR-200a regulates Nrf2 activation by targeting _Keap1_ mRNA in breast cancer cells The Journal of Biological Chemistry 2011 286 47 40725 40733 10.1074/jbc.M111.275495 2-s2.0-81755171451 21926171 PMC3220489
52 Zhang N. Zeng X. Sun C. LncRNA LINC00963 promotes tumorigenesis and radioresistance in breast cancer by sponging miR-324-3p and inducing ACK1 expression Molecular Therapy-Nucleic Acids 2019 18 871 881 10.1016/j.omtn.2019.09.033 31751910 PMC6881674
53 Chen D. Dang B. L. Huang J. Z. MiR-373 drives the epithelial-to-mesenchymal transition and metastasis via the miR-373-TXNIP-HIF1alpha-TWIST signaling axis in breast cancer Oncotarget 2015 6 32701 32712 10.18632/oncotarget.4702 2-s2.0-84946076051 26196741 PMC4741723
54 Ahir M. Upadhyay P. Ghosh A. Delivery of dual miRNA through CD44-targeted mesoporous silica nanoparticles for enhanced and effective triple-negative breast cancer therapy Biomaterials Science 2020 8 10 2939 2954 10.1039/d0bm00015a 32319481
55 Liu X. Tang H. Chen J. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer Oncotarget 2015 6 24 20070 20083 10.18632/oncotarget.4039 2-s2.0-84940208320 26036638 PMC4652988
56 Zheng M. Wu Z. Wu A. Huang Z. He N. Xie X. MiR-145 promotes TNF- α -induced apoptosis by facilitating the formation of RIP1-FADDcaspase-8 complex in triple-negative breast cancer Tumour Biology 2016 37 7 8599 8607 10.1007/s13277-015-4631-4 2-s2.0-84953302488 26733177
57 Sun X. Li Y. Zheng M. Zuo W. Zheng W. MicroRNA-223 increases the sensitivity of triple-negative breast cancer stem cells to TRAIL-induced apoptosis by targeting HAX-1 PLoS One 2016 11 9, article e0162754 10.1371/journal.pone.0162754 2-s2.0-85029198835 27618431 PMC5019415
58 Patel N. Garikapati K. R. Ramaiah M. J. Polavarapu K. K. Bhadra U. Bhadra M. P. miR-15a/miR-16 induces mitochondrial dependent apoptosis in breast cancer cells by suppressing oncogene BMI1 Life Sciences 2016 164 60 70 10.1016/j.lfs.2016.08.028 2-s2.0-84991728487 27596816
59 Lu P. Gu Y. Li L. Wang F. Yang X. Yang Y. Long noncoding RNA CAMTA1 promotes proliferation and mobility of the human breast cancer cell line MDA-MB-231 via targeting miR-20b Oncology Research 2018 26 4 625 635 10.3727/096504017X14953948675395 2-s2.0-85046939062 28550685 PMC7844752
60 Zhang L. Zhang X. Wang X. He M. Qiao S. MicroRNA-224 promotes tumorigenesis through downregulation of caspase-9 in triple-negative breast cancer Disease Markers 2019 2019 9 7378967 10.1155/2019/7378967 2-s2.0-85062278883 30886656 PMC6388334
61 Chan D. C. Mitochondrial dynamics and its involvement in disease Annual Review of Pathology 2020 15 1 235 259 10.1146/annurev-pathmechdis-012419-032711 31585519
62 Legros F. Lombes A. Frachon P. Rojo M. Mitochondrial fusion in human cells is efficient, requires the inner membrane potential, and is mediated by mitofusins Molecular Biology of the Cell 2002 13 12 4343 4354 10.1091/mbc.e02-06-0330 2-s2.0-0036906665 12475957 PMC138638
63 Koshiba T. Detmer S. A. Kaiser J. T. Chen H. McCaffery J. M. Chan D. C. Structural basis of mitochondrial tethering by mitofusin complexes Science 2004 305 5685 858 862 10.1126/science.1099793 2-s2.0-3843075121 15297672
64 Mishra P. Carelli V. Manfredi G. Chan D. C. Proteolytic cleavage of Opa1 stimulates mitochondrial inner membrane fusion and couples fusion to oxidative phosphorylation Cell Metabolism 2014 19 4 630 641 10.1016/j.cmet.2014.03.011 2-s2.0-84897538678 24703695 PMC4018240
65 Pagliuso A. Cossart P. Stavru F. The ever-growing complexity of the mitochondrial fission machinery Cellular and Molecular Life Sciences 2018 75 3 355 374 10.1007/s00018-017-2603-0 2-s2.0-85026801288 28779209 PMC5765209
66 Jimah J. R. Hinshaw J. E. Structural insights into the mechanism of dynamin superfamily proteins Trends in Cell Biology 2019 29 3 257 273 10.1016/j.tcb.2018.11.003 2-s2.0-85057794280 30527453 PMC9623552
67 Loson O. C. Song Z. Chen H. Chan D. C. Fis1, Mff, MiD49, and MiD51 mediate Drp1 recruitment in mitochondrial fission Molecular Biology of the Cell 2013 24 5 659 667 10.1091/mbc.E12-10-0721 2-s2.0-84874639591 23283981 PMC3583668
68 Osellame L. D. Singh A. P. Stroud D. A. Cooperative and independent roles of the Drp1 adaptors Mff, MiD49 and MiD51 in mitochondrial fission Journal of Cell Science 2016 129 11 2170 2181 10.1242/jcs.185165 2-s2.0-84976477426 27076521 PMC6919635
69 Otera H. Miyata N. Kuge O. Mihara K. Drp1-dependent mitochondrial fission via MiD49/51 is essential for apoptotic cristae remodeling The Journal of Cell Biology 2016 212 5 531 544 10.1083/jcb.201508099 2-s2.0-84960428273 26903540 PMC4772499
70 Purohit P. K. Edwards R. Tokatlidis K. Saini N. MiR-195 regulates mitochondrial function by targeting mitofusin-2 in breast cancer cells RNA Biology 2019 16 7 918 929 10.1080/15476286.2019.1600999 2-s2.0-85065032373 30932749 PMC6546347
71 Zhang S. Liu C. Zhang X. Mitochondrial damage mediated by miR-1 overexpression in cancer stem cells Molecular Therapy-Nucleic Acids 2019 18 938 953 10.1016/j.omtn.2019.10.016 31765945 PMC6883328
72 Hu Q. Yuan Y. Wu Y. Huang Y. Zhao Z. Xiao C. MicroRNA‑137 exerts protective effects on hypoxia‑induced cell injury by inhibiting autophagy/mitophagy and maintaining mitochondrial function in breast cancer stem‑like cells Oncology Reports 2020 2020 p. 1 10.3892/or.2020.7714 PMC7448477 32945512
73 Peruzzo R. Costa R. Bachmann M. Leanza L. Szabo I. Mitochondrial metabolism, contact sites and cellular calcium signaling: implications for tumorigenesis Cancers 2020 12 9 p. 2574 10.3390/cancers12092574 32927611 PMC7564994
74 Zheng X. Lu S. He Z. MCU-dependent negative sorting of miR-4488 to extracellular vesicles enhances angiogenesis and promotes breast cancer metastatic colonization Oncogene 2020 39 46 6975 6989 10.1038/s41388-020-01514-6 33067576
75 Fan X. Zhou S. Zheng M. Deng X. Yi Y. Huang T. MiR-199a-3p enhances breast cancer cell sensitivity to cisplatin by downregulating TFAM (TFAM) Biomedicine & Pharmacotherapy 2017 88 507 514 10.1016/j.biopha.2017.01.058 2-s2.0-85010190235 28126676
76 Mandal S. Gamit N. Varier L. Dharmarajan A. Warrier S. Inhibition of breast cancer stem-like cells by a triterpenoid, ursolic acid, via activation of Wnt antagonist, sFRP4 and suppression of miRNA-499a-5p Life Sciences 2021 265 p. 118854 10.1016/j.lfs.2020.118854 33278391
77 Kim D. Lee J. Kang J. Notch1 in tumor microvascular endothelial cells and tumoral miR-34a as prognostic markers in locally advanced triple-negative breast cancer Journal of Breast Cancer 2019 22 4 562 578 10.4048/jbc.2019.22.e56 31897330 PMC6933032
78 Hu G. Zhao X. Wang J. miR-125b regulates the drug-resistance of breast cancer cells to doxorubicin by targeting HAX-1 Oncology Letters 2017 15 1621 1629 10.3892/ol.2017.7476 2-s2.0-85038447482 29434858 PMC5774474
79 Qattan A. Intabli H. Alkhayal W. Eltabache C. Tweigieri T. Amer S. B. Robust expression of tumor suppressor miRNA's let-7 and miR-195 detected in plasma of Saudi female breast cancer patients BMC Cancer 2017 17 1 p. 799 10.1186/s12885-017-3776-5 2-s2.0-85035339312 29183284 PMC5706292
80 Ye Z. Hao R. Cai Y. Wang X. Huang G. Knockdown of miR-221 promotes the cisplatin-inducing apoptosis by targeting the BIM-Bax/Bak axis in breast cancer Tumour Biology 2016 37 4 4509 4515 10.1007/s13277-015-4267-4 2-s2.0-84945245355 26503209
81 Zhou S. Huang Q. Zheng S. Lin K. You J. Zhang X. miR-27a regulates the sensitivity of breast cancer cells to cisplatin treatment via BAK-SMAC/DIABLO-XIAP axis Tumour Biology 2016 37 5 6837 6845 10.1007/s13277-015-4500-1 2-s2.0-84949546603 26662313
82 Pradhan A. K. Bhoopathi P. Talukdar S. MDA-7/IL-24 regulates the miRNA processing enzyme DICER through downregulation of MITF Proceedings of the National Academy of Sciences of the United States of America 2019 116 12 5687 5692 10.1073/pnas.1819869116 2-s2.0-85063264692 30842276 PMC6431152
83 Ahir M. Bhattacharya S. Karmakar S. Tailored-CuO-nanowire decorated with folic acid mediated coupling of the mitochondrial-ROS generation and miR425-PTEN axis in furnishing potent anti-cancer activity in human triple negative breast carcinoma cells Biomaterials 2016 76 115 132 10.1016/j.biomaterials.2015.10.044 2-s2.0-84961214791 26520043
84 De Blasio A. Di Fiore R. Pratelli G. A loop involving NRF2, miR-29b-1-5p and AKT, regulates cell fate of MDA-MB-231 triple-negative breast cancer cells Journal of Cellular Physiology 2019 235 2 629 637 10.1002/jcp.29062 2-s2.0-85069939334 31313842
85 Shi D. Guo L. Sun X. UTMD inhibit EMT of breast cancer through the ROS/miR-200c/ZEB1 axis Scientific Reports 2020 10 1 p. 6657 10.1038/s41598-020-63653-w 32313093 PMC7170845
86 van Zandwijk N. Pavlakis N. Kao S. C. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study The Lancet Oncology 2017 18 10 1386 1396 10.1016/S1470-2045(17)30621-6 2-s2.0-85028676559 28870611